Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Gritstone Announces First Patient Enrolled For Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE For First Line (1L) Maintenance Treatment Of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)


Benzinga | Jan 13, 2022 11:44AM EST

Gritstone Announces First Patient Enrolled For Phase 2/3 Trial Evaluating Individualized Neoantigen Vaccine GRANITE For First Line (1L) Maintenance Treatment Of Metastatic, Microsatellite-Stable Colorectal Cancer (MSS-CRC)






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC